Single User License
INR 96780
Site License
INR 193560
Corporate User License
INR 290340

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


OncoMed Pharmaceuticals, Inc.-Product Pipeline Review-2015

OncoMed Pharmaceuticals, Inc.-Product Pipeline Review-2015


  • Products Id :- GMDHC07416CDB
  • |
  • Pages: 59
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

OncoMed Pharmaceuticals, Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'OncoMed Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the OncoMed Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OncoMed Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of OncoMed Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of OncoMed Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the OncoMed Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate OncoMed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of OncoMed Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the OncoMed Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of OncoMed Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of OncoMed Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of OncoMed Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

OncoMed Pharmaceuticals, Inc. Snapshot 5

OncoMed Pharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

OncoMed Pharmaceuticals, Inc.-Research and Development Overview 6

Key Therapeutic Areas 6

OncoMed Pharmaceuticals, Inc.-Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products-Monotherapy 10

Pipeline Products-Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

OncoMed Pharmaceuticals, Inc.-Pipeline Products Glance 13

OncoMed Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

OncoMed Pharmaceuticals, Inc.-Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

OncoMed Pharmaceuticals, Inc.-Drug Profiles 16

demcizumab 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

tarextumab 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

brontictuzumab 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ipafricept 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

OMP-131R10 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

OMP-305B83 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

vantictumab 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Biologic to Inhibit Wnt Pathway for Cancer 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Biologic to Target Hippo Pathway for Cancer 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody for Oncology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody to Inhibit Other Pathways for Cancer 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Recombinant Protein to Agonize GITR for Oncology 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

OncoMed Pharmaceuticals, Inc.-Pipeline Analysis 37

OncoMed Pharmaceuticals, Inc.-Pipeline Products by Target 37

OncoMed Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 38

OncoMed Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 39

OncoMed Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 40

OncoMed Pharmaceuticals, Inc.-Recent Pipeline Updates 41

OncoMed Pharmaceuticals, Inc.-Dormant Projects 56

OncoMed Pharmaceuticals, Inc.-Locations And Subsidiaries 57

Head Office 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

OncoMed Pharmaceuticals, Inc., Key Information 5

OncoMed Pharmaceuticals, Inc., Key Facts 5

OncoMed Pharmaceuticals, Inc.-Pipeline by Indication, 2015 7

OncoMed Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 9

OncoMed Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 10

OncoMed Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 11

OncoMed Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 12

OncoMed Pharmaceuticals, Inc.-Phase II, 2015 13

OncoMed Pharmaceuticals, Inc.-Phase I, 2015 14

OncoMed Pharmaceuticals, Inc.-Preclinical, 2015 15

OncoMed Pharmaceuticals, Inc.-Pipeline by Target, 2015 37

OncoMed Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 38

OncoMed Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 39

OncoMed Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 40

OncoMed Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 41

OncoMed Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 56

List of Figures

OncoMed Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 7

OncoMed Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 9

OncoMed Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 10

OncoMed Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 37

OncoMed Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 38

OncoMed Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 39

OncoMed Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc. - Key Therapeutics; OncoMed Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; OncoMed Pharmaceuticals, Inc. - News; OncoMed Pharmaceuticals, Inc. - Latest Updates; OncoMed Pharmaceuticals, Inc. - Pipeline; OncoMed Pharmaceuticals, Inc. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com